Capricor Therapeutics (CAPR) Enterprise Value (2010 - 2026)

Capricor Therapeutics' Enterprise Value history runs 17 years deep, the most recent figure standing at -$278.6 million for Q1 2026.

• On a quarterly basis, Enterprise Value fell 92.44% year-over-year to -$278.6 million in Q1 2026; TTM through Mar 2026 was -$278.6 million, a 92.44% decrease from a year earlier, with the FY2025 full-year figure at -$318.1 million, down 109.96% from the prior year.
• Enterprise Value climbed to -$278.6 million in Q1 2026 per CAPR's latest filing, from -$318.1 million in the prior quarter.
• Across five years, Enterprise Value topped out at -$28.5 million in Q3 2023 and bottomed at -$318.1 million in Q4 2025.
• The 5-year median for Enterprise Value is -$51.4 million (2022), against an average of -$95.1 million.
• Across the five-year window, Enterprise Value surged 38.81% in 2023 and slumped 316.81% in 2025, its largest moves.
• Year by year, Enterprise Value stood at -$41.4 million in 2022, then grew by 4.67% to -$39.5 million in 2023, then plunged by 283.7% to -$151.5 million in 2024, then slumped by 109.96% to -$318.1 million in 2025, then climbed by 12.42% to -$278.6 million in 2026.
• Per Business Quant, the three latest CAPR Enterprise Value figures stand at -$278.6 million (Q1 2026), -$318.1 million (Q4 2025), and -$98.6 million (Q3 2025).